Skip to main content
. 2022 Feb 24;13(2):135–146. doi: 10.5306/wjco.v13.i2.135

Figure 1.

Figure 1

Percentage of patients with different breast cancer molecular sub-types among the neurotrophic receptor tyrosine kinase amplified and non-amplified groups. Data are from TCGA breast cancer cohort. Black columns: Neurotrophic receptor tyrosine kinase amplified; Grey columns: Neurotrophic receptor tyrosine kinase non-amplified.